摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(2,4-Dioxo-4H-benzo[d][1,3]oxazin-1-yl)-butyric acid ethyl ester | 88267-65-6

中文名称
——
中文别名
——
英文名称
4-(2,4-Dioxo-4H-benzo[d][1,3]oxazin-1-yl)-butyric acid ethyl ester
英文别名
Ethyl 4-(2,4-dioxo-3,1-benzoxazin-1-yl)butanoate
4-(2,4-Dioxo-4H-benzo[d][1,3]oxazin-1-yl)-butyric acid ethyl ester化学式
CAS
88267-65-6
化学式
C14H15NO5
mdl
——
分子量
277.277
InChiKey
DZSBJXKKPAVAHZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    20
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    72.9
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-(2,4-Dioxo-4H-benzo[d][1,3]oxazin-1-yl)-butyric acid ethyl esterammonium hydroxide 作用下, 以56%的产率得到2-(3-ethoxycarbonylpropylamino)benzamide
    参考文献:
    名称:
    Ozaki, Ken-Ichi; Yamada, Yoshihisa; Oine, Toyonari, Chemical and pharmaceutical bulletin, 1983, vol. 31, # 7, p. 2234 - 2243
    摘要:
    DOI:
  • 作为产物:
    描述:
    靛红酸酐4-溴丁酸乙酯 在 sodium hydride 作用下, 以 N,N-二甲基乙酰胺 为溶剂, 反应 20.0h, 生成 4-(2,4-Dioxo-4H-benzo[d][1,3]oxazin-1-yl)-butyric acid ethyl ester
    参考文献:
    名称:
    3-(1,1-Dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, Potent Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase
    摘要:
    Recently, we disclosed a new class of HCV polymerase inhibitors discovered through high-throughput screening (HTS) of the GlaxoSmithKline proprietary compound collection. This interesting class of 3-(1,1-dioxo-2H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones potently inhibits HCV polymerase enzymatic activity and inhibits the ability of the subgenomic HCV replicon to replicate in Huh-7 cells. This report will focus on the structure-activity relationships (SAR) of substituents on the quinolinone ring, culminating in the discovery of 1-(2-cyclopropylethyl)-3-(1,1-dioxo-2H-1,2,4-benzothiadiazin-3-yl)-6-fluoro-4-hydroxy-2(1H)-quinolinone (130), an inhibitor with excellent potency in biochemical and cellular assays possessing attractive molecular properties for advancement as a clinical candidate. The potential for development and safety assessment profile of compound 130 will also be discussed.
    DOI:
    10.1021/jm050855s
点击查看最新优质反应信息

文献信息

  • 3-(1,1-Dioxo-2<i>H</i>-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1<i>H</i>)-quinolinones, Potent Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase
    作者:Rosanna Tedesco、Antony N. Shaw、Ramesh Bambal、Deping Chai、Nestor O. Concha、Michael G. Darcy、Dashyant Dhanak、Duke M. Fitch、Adam Gates、Warren G. Gerhardt、Dina L. Halegoua、Chao Han、Glenn A. Hofmann、Victor K. Johnston、Arun C. Kaura、Nannan Liu、Richard M. Keenan、Juili Lin-Goerke、Robert T. Sarisky、Kenneth J. Wiggall、Michael N. Zimmerman、Kevin J. Duffy
    DOI:10.1021/jm050855s
    日期:2006.2.1
    Recently, we disclosed a new class of HCV polymerase inhibitors discovered through high-throughput screening (HTS) of the GlaxoSmithKline proprietary compound collection. This interesting class of 3-(1,1-dioxo-2H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones potently inhibits HCV polymerase enzymatic activity and inhibits the ability of the subgenomic HCV replicon to replicate in Huh-7 cells. This report will focus on the structure-activity relationships (SAR) of substituents on the quinolinone ring, culminating in the discovery of 1-(2-cyclopropylethyl)-3-(1,1-dioxo-2H-1,2,4-benzothiadiazin-3-yl)-6-fluoro-4-hydroxy-2(1H)-quinolinone (130), an inhibitor with excellent potency in biochemical and cellular assays possessing attractive molecular properties for advancement as a clinical candidate. The potential for development and safety assessment profile of compound 130 will also be discussed.
  • Ozaki, Ken-Ichi; Yamada, Yoshihisa; Oine, Toyonari, Chemical and pharmaceutical bulletin, 1983, vol. 31, # 7, p. 2234 - 2243
    作者:Ozaki, Ken-Ichi、Yamada, Yoshihisa、Oine, Toyonari
    DOI:——
    日期:——
查看更多